{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:43:30Z","timestamp":1792583010184,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>GSTP1 promoter hypermethylation is one of the most consistently documented molecular alterations in prostate cancer, with high prevalence in malignant tissue and a well-established relationship with transcriptional silencing. However, despite more than two decades of biological and diagnostic investigation, GSTP1-based testing has not acquired a clearly defined stand-alone role in contemporary prostate cancer detection. This narrative review examines why extensive biological evidence has not translated into routine clinical use and where, if anywhere, GSTP1 testing might provide meaningful value within current diagnostic pathways. Evidence from prostate tissue, urine and circulating cell-free DNA is considered alongside the effects of biospecimen selection, preanalytical handling, CpG target selection, assay design and interpretation thresholds. Tissue demonstrates the most reproducible signal and has achieved partial clinical translation through multiplex testing such as ConfirmMDx, whereas urinary and blood-based approaches remain investigational. Recent urinary findings, including in men with moderately elevated PSA, are promising but remain preliminary and have not established incremental value beyond contemporary risk assessment, biomarkers and multiparametric MRI. The translational priority is therefore not to demonstrate again that GSTP1 detects prostate cancer, but to determine whether a standardised assay provides reproducible, nonredundant and clinically actionable information at a defined decision point. Future development should prioritise clearly specified target populations, analytically validated assay configurations, clinically significant prostate cancer as the relevant endpoint, and prospective evaluation against contemporary diagnostic pathways.<\/jats:p>","DOI":"10.1007\/s11033-026-13011-2","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:11:39Z","timestamp":1792581099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GSTP1 promoter hypermethylation in prostate cancer detection: current evidence, clinical positioning, and translational gaps"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1663-5874","authenticated-orcid":false,"given":"Jun-Lynn","family":"Joo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7738-9398","authenticated-orcid":false,"given":"Rebecca Shin-Yee","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1006-3649","authenticated-orcid":false,"given":"Bey Hing","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-7678","authenticated-orcid":false,"given":"Nancy Choon-Si","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"13011_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"13011_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","volume":"87","author":"EJ Schafer","year":"2025","unstructured":"Schafer EJ, Laversanne M, Sung H et al (2025) Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update. Eur Urol 87:302\u2013313. https:\/\/doi.org\/10.1016\/j.eururo.2024.11.013","journal-title":"Eur Urol"},{"key":"13011_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12916-021-02230-y","volume":"20","author":"SWD Merriel","year":"2022","unstructured":"Merriel SWD, Pocock L, Gilbert E et al (2022) Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med 20:54. https:\/\/doi.org\/10.1186\/s12916-021-02230-y","journal-title":"BMC Med"},{"key":"13011_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/JU.0000000000004995","volume":"215","author":"DW Lin","year":"2026","unstructured":"Lin DW, Carlsson S, Filson CP et al (2026) Updates to Early Detection of Prostate Cancer: AUA\/SUO Guideline (2026). J Urol 215:491\u2013501. https:\/\/doi.org\/10.1097\/JU.0000000000004995","journal-title":"J Urol"},{"key":"13011_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/JU.0000000000003492","volume":"210","author":"JT Wei","year":"2023","unstructured":"Wei JT, Barocas D, Carlsson S et al (2023) Early Detection of Prostate Cancer: AUA\/SUO Guideline Part II: Considerations for a Prostate Biopsy. J Urol 210:54\u201363. https:\/\/doi.org\/10.1097\/JU.0000000000003492","journal-title":"J Urol"},{"key":"13011_CR6","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.eururo.2004.06.014","volume":"46","author":"R Henrique","year":"2004","unstructured":"Henrique R, Jer\u00f3nimo C (2004) Molecular Detection of Prostate Cancer: A Role for GSTP1 Hypermethylation. Eur Urol 46:660\u2013669. https:\/\/doi.org\/10.1016\/j.eururo.2004.06.014","journal-title":"Eur Urol"},{"key":"13011_CR7","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/S0002-9440(10)63028-3","volume":"159","author":"X Lin","year":"2001","unstructured":"Lin X, Tascilar M, Lee W-H et al (2001) GSTP1 CpG Island Hypermethylation Is Responsible for the Absence of GSTP1 Expression in Human Prostate Cancer Cells. Am J Pathol 159:1815\u20131826. https:\/\/doi.org\/10.1016\/S0002-9440(10)63028-3","journal-title":"Am J Pathol"},{"key":"13011_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41585-024-00991-8","volume":"22","author":"V Const\u00e2ncio","year":"2025","unstructured":"Const\u00e2ncio V, Lobo J, Sequeira JP et al (2025) Prostate cancer epigenetics \u2014 from pathophysiology to clinical application. Nat Rev Urol 22:447\u2013469. https:\/\/doi.org\/10.1038\/s41585-024-00991-8","journal-title":"Nat Rev Urol"},{"key":"13011_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1158\/1940-6207.CAPR-22-0485","volume":"16","author":"H Gupta","year":"2023","unstructured":"Gupta H, Inoue H, Nakai Y et al (2023) Progressive Spreading of DNA Methylation in the GSTP1 Promoter CpG Island across Transitions from Precursors to Invasive Prostate Cancer. Cancer Prev Res 16:449\u2013460. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-22-0485","journal-title":"Cancer Prev Res"},{"key":"13011_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/4358292","volume":"2016","author":"F Martignano","year":"2016","unstructured":"Martignano F, Gurioli G, Salvi S et al (2016) GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications. Dis Markers 2016:1\u20136. https:\/\/doi.org\/10.1155\/2016\/4358292","journal-title":"Dis Markers"},{"key":"13011_CR11","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/bco2.445","volume":"5","author":"R Pidsley","year":"2024","unstructured":"Pidsley R, Lam D, Qu W et al (2024) Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer. BJUI Compass 5:1299\u20131306. https:\/\/doi.org\/10.1002\/bco2.445","journal-title":"BJUI Compass"},{"key":"13011_CR12","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.3390\/cancers13246234","volume":"13","author":"O Bryzgunova","year":"2021","unstructured":"Bryzgunova O, Bondar A, Ruzankin P et al (2021) Locus-Specific Methylation of GSTP1, RNF219, and KIAA1539 Genes with Single Molecule Resolution in Cell-Free DNA from Healthy Donors and Prostate Tumor Patients: Application in Diagnostics. Cancers 13:6234. https:\/\/doi.org\/10.3390\/cancers13246234","journal-title":"Cancers"},{"key":"13011_CR13","unstructured":"Goessl C, Krause H, Miller K (2000) Fluorescent Methylation-specific Polymerase Chain Reaction for DNA-based Detection of Prostate Cancer in Bodily Fluids 60:5941\u20135945"},{"key":"13011_CR14","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1158\/1078-0432.CCR-06-2467","volume":"13","author":"M Roupr\u00eat","year":"2007","unstructured":"Roupr\u00eat M, Hupertan V, Yates DR et al (2007) Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage. Clin Cancer Res 13:1720\u20131725. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2467","journal-title":"Clin Cancer Res"},{"key":"13011_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/bjc.2011.143","volume":"105","author":"T Wu","year":"2011","unstructured":"Wu T, Giovannucci E, Welge J et al (2011) Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Br J Cancer 105:65\u201373. https:\/\/doi.org\/10.1038\/bjc.2011.143","journal-title":"Br J Cancer"},{"key":"13011_CR16","doi-asserted-by":"publisher","first-page":"454","DOI":"10.21037\/tau-24-382","volume":"14","author":"F Barletta","year":"2025","unstructured":"Barletta F, Bandini M, Cirulli GO et al (2025) DNA methylation alterations in prostate cancer: from diagnosis to treatment. Transl Androl Urol 14:454\u2013462. https:\/\/doi.org\/10.21037\/tau-24-382","journal-title":"Transl Androl Urol"},{"key":"13011_CR17","doi-asserted-by":"publisher","first-page":"1182727","DOI":"10.3389\/fonc.2023.1182727","volume":"13","author":"HJ Shin","year":"2023","unstructured":"Shin HJ, Hua JT, Li H (2023) Recent advances in understanding DNA methylation of prostate cancer. Front Oncol 13:1182727. https:\/\/doi.org\/10.3389\/fonc.2023.1182727","journal-title":"Front Oncol"},{"key":"13011_CR18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/PPO.0000000000000672","volume":"29","author":"AK Cani","year":"2023","unstructured":"Cani AK, Salami SS (2023) Recent Advances in Blood-Based Liquid Biopsy Approaches in Prostate Cancer. Cancer J 29:220\u2013225. https:\/\/doi.org\/10.1097\/PPO.0000000000000672","journal-title":"Cancer J"},{"key":"13011_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3390\/cancers18030389","volume":"18","author":"J Robaczy\u0144ska","year":"2026","unstructured":"Robaczy\u0144ska J, Maj M, Kilja\u0144czyk A et al (2026) Epigenetic and Liquid Biopsy Biomarkers in Prostate Cancer: Bridging Tumor Heterogeneity and Clinical Implementation. Cancers 18:389. https:\/\/doi.org\/10.3390\/cancers18030389","journal-title":"Cancers"},{"key":"13011_CR20","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41416-022-01881-9","volume":"127","author":"B Trujillo","year":"2022","unstructured":"Trujillo B, Wu A, Wetterskog D, Attard G (2022) Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. Br J Cancer 127:1394\u20131402. https:\/\/doi.org\/10.1038\/s41416-022-01881-9","journal-title":"Br J Cancer"},{"key":"13011_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2023\/7279243","volume":"2023","author":"J Ye","year":"2023","unstructured":"Ye J, Wu M, He L et al (2023) Glutathione-S-Transferase p 1 Gene Promoter Methylation in Cell-Free DNA as a Diagnostic and Prognostic Tool for Prostate Cancer: A Systematic Review and Meta-Analysis. Int J Endocrinol 2023:1\u20139. https:\/\/doi.org\/10.1155\/2023\/7279243","journal-title":"Int J Endocrinol"},{"key":"13011_CR22","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2020.4979","author":"J Cui","year":"2020","unstructured":"Cui J, Li G, Yin J et al (2020) GSTP1 and cancer: Expression, methylation, polymorphisms and signaling (Review). Int J Oncol. https:\/\/doi.org\/10.3892\/ijo.2020.4979","journal-title":"Int J Oncol"},{"key":"13011_CR23","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3390\/ijms27052249","volume":"27","author":"WCH Visser","year":"2026","unstructured":"Visser WCH, De Jong H, Janssen LB et al (2026) Impact of Heterogeneous DNA Methylation on the Accuracy of Quantitative Methylation-Specific PCR for Detecting DNA Hypermethylation in Prostate Cancer. IJMS 27:2249. https:\/\/doi.org\/10.3390\/ijms27052249","journal-title":"IJMS"},{"key":"13011_CR24","doi-asserted-by":"publisher","first-page":"1385041","DOI":"10.3389\/fcell.2024.1385041","volume":"12","author":"H Peng","year":"2024","unstructured":"Peng H, Pan M, Zhou Z et al (2024) The impact of preanalytical variables on the analysis of cell-free DNA from blood and urine samples. Front Cell Dev Biol 12:1385041. https:\/\/doi.org\/10.3389\/fcell.2024.1385041","journal-title":"Front Cell Dev Biol"},{"key":"13011_CR25","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1038\/s41388-025-03624-5","volume":"44","author":"H Pharo","year":"2025","unstructured":"Pharo H, Vedeld HM, Sjurgard IV et al (2025) From concept to clinic: a roadmap for DNA methylation biomarkers in liquid biopsies. Oncogene 44:4814\u20134831. https:\/\/doi.org\/10.1038\/s41388-025-03624-5","journal-title":"Oncogene"},{"key":"13011_CR26","unstructured":"Cairns P, Esteller M, Herman JG et al (2001) Molecular Detection of Prostate Cancer in Urine by GSTP1 Hypermethylation. Clinical Cancer Research 7:2727\u20132730"},{"key":"13011_CR27","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.21037\/tau-2024-689","volume":"14","author":"R Ji","year":"2025","unstructured":"Ji R, Zhang L, Xing Y et al (2025) Clinical significance of urine-based automated detection of GSTP1 methylation for the diagnosis of suspected prostate cancer patients. Transl Androl Urol 14:1204\u20131213. https:\/\/doi.org\/10.21037\/tau-2024-689","journal-title":"Transl Androl Urol"},{"key":"13011_CR28","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.3390\/cancers16112001","volume":"16","author":"T Rendek","year":"2024","unstructured":"Rendek T, Pos O, Duranova T et al (2024) Current Challenges of Methylation-Based Liquid Biopsies in Cancer Diagnostics. Cancers 16:2001. https:\/\/doi.org\/10.3390\/cancers16112001","journal-title":"Cancers"},{"key":"13011_CR29","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","volume":"15","author":"NM Fonseca","year":"2024","unstructured":"Fonseca NM, Maurice-Dror C, Herberts C et al (2024) Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat Commun 15:1828. https:\/\/doi.org\/10.1038\/s41467-024-45475-w","journal-title":"Nat Commun"},{"key":"13011_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-1-61779-316-5_3","volume-title":"Epigenetics Protocols","author":"J-L Ku","year":"2011","unstructured":"Ku J-L, Jeon Y-K, Park J-G (2011) Methylation-Specific PCR. In: Tollefsbol TO (ed) Epigenetics Protocols. Humana, Totowa, NJ, pp 23\u201332"},{"key":"13011_CR31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/978-1-4939-7481-8_23","volume-title":"DNA Methylation Protocols","author":"J Ramalho-Carvalho","year":"2018","unstructured":"Ramalho-Carvalho J, Henrique R, Jer\u00f3nimo C (2018) Methylation-Specific PCR. In: Tost J (ed) DNA Methylation Protocols. Springer New York, New York, NY, pp 447\u2013472"},{"key":"13011_CR32","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s11033-025-10812-9","volume":"52","author":"I Mharrach","year":"2025","unstructured":"Mharrach I, Aqerrout M, Tadlaoui KA et al (2025) Methylation status of GSTP1 and APC promoter genes as potential biomarkers for early detection and tumor aggressiveness in prostate cancer: insights from a Moroccan cohort. Mol Biol Rep 52:711. https:\/\/doi.org\/10.1007\/s11033-025-10812-9","journal-title":"Mol Biol Rep"},{"key":"13011_CR33","doi-asserted-by":"publisher","first-page":"8014","DOI":"10.22037\/uj.v20i.8014","volume":"20","author":"E Aykanli","year":"2024","unstructured":"Aykanli E, Arisan S, Arisan ED, Yavuzsan AH (2024) Diagnostic Value of GSTP1, RASSF1, AND RASSF2 Methylation in Serum of Prostate Cancer Patients. Urol J 20:8014. https:\/\/doi.org\/10.22037\/uj.v20i.8014","journal-title":"Urol J"},{"key":"13011_CR34","doi-asserted-by":"publisher","first-page":"1800705","DOI":"10.3389\/fonc.2026.1800705","volume":"16","author":"WD Cleanclay","year":"2026","unstructured":"Cleanclay WD, Kintung IF, Kernyuy FB et al (2026) Liquid biopsy\u2013based epigenetic signatures for early detection of prostate cancer: a systematic review. Front Oncol 16:1800705. https:\/\/doi.org\/10.3389\/fonc.2026.1800705","journal-title":"Front Oncol"},{"key":"13011_CR35","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.3390\/life14081024","volume":"14","author":"P Shah","year":"2024","unstructured":"Shah P, Taylor WR, Negaard BJ et al (2024) Methylated DNA Markers in Voided Urine for the Identification of Clinically Significant Prostate Cancer. Life 14:1024. https:\/\/doi.org\/10.3390\/life14081024","journal-title":"Life"},{"key":"13011_CR36","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/MOU.0000000000001308","volume":"35","author":"KD Assani","year":"2025","unstructured":"Assani KD, Pierce JM, Galloway LA, Tosoian JJ (2025) Blood- and urine-based biomarkers for the detection of clinically significant prostate cancer: a contemporary review. Curr Opin Urol 35:590\u2013596. https:\/\/doi.org\/10.1097\/MOU.0000000000001308","journal-title":"Curr Opin Urol"},{"key":"13011_CR37","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.euros.2025.03.006","volume":"75","author":"TFW Soeterik","year":"2025","unstructured":"Soeterik TFW, Wu X, Van Den Bergh RCN et al (2025) Personalised Prostate Cancer Diagnosis: Evaluating Biomarker-based Approaches to Reduce Unnecessary Magnetic Resonance Imaging and Biopsy Procedures. Eur Urol Open Sci 75:106\u2013119. https:\/\/doi.org\/10.1016\/j.euros.2025.03.006","journal-title":"Eur Urol Open Sci"},{"key":"13011_CR38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/cpt.3416","volume":"117","author":"CM Lockwood","year":"2025","unstructured":"Lockwood CM, Merker JD, Bain E et al (2025) Towards Preanalytical Best Practices for Liquid Biopsy Studies: A BLOODPAC Landscape Analysis. Clin Pharma Ther 117:28\u201333. https:\/\/doi.org\/10.1002\/cpt.3416","journal-title":"Clin Pharma Ther"},{"key":"13011_CR39","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jmoldx.2023.09.004","volume":"25","author":"CM Lockwood","year":"2023","unstructured":"Lockwood CM, Borsu L, Cankovic M et al (2023) Recommendations for Cell-Free DNA Assay Validations. J Mol Diagn 25:876\u2013897. https:\/\/doi.org\/10.1016\/j.jmoldx.2023.09.004","journal-title":"J Mol Diagn"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-13011-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-13011-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-13011-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:11:41Z","timestamp":1792581101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-13011-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["13011"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-13011-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"24 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article is a review and does not report any original data involving human participants or animals. Therefore, ethical approval was not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have reviewed and approved the final version of the manuscript and consent to its submission for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1777"}}